Your browser is no longer supported. Please, upgrade your browser.
ADIL Adial Pharmaceuticals, Inc. daily Stock Chart
Adial Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.87 Insider Own34.27% Shs Outstand10.03M Perf Week-9.06%
Market Cap30.19M Forward P/E- EPS next Y-0.95 Insider Trans- Shs Float6.38M Perf Month-24.18%
Income-10.80M PEG- EPS next Q- Inst Own2.80% Short Float3.70% Perf Quarter-17.31%
Sales- P/S- EPS this Y-171.20% Inst Trans- Short Ratio0.28 Perf Half Y3.79%
Book/sh0.89 P/B3.38 EPS next Y-8.00% ROA-775.40% Target Price5.50 Perf Year-
Cash/sh0.48 P/C6.29 EPS next 5Y- ROE- 52W Range1.11 - 9.44 Perf YTD-41.21%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.11% Beta-
Dividend %- Quick Ratio16.20 Sales past 5Y- Gross Margin- 52W Low172.27% ATR0.40
Employees3 Current Ratio16.20 Sales Q/Q- Oper. Margin- RSI (14)37.24 Volatility10.23% 9.95%
OptionableNo Debt/Eq0.02 EPS Q/Q- Profit Margin- Rel Volume0.16 Prev Close3.11
ShortableYes LT Debt/Eq0.00 EarningsMar 20 Payout- Avg Volume837.36K Price3.01
Recom2.00 SMA20-12.41% SMA50-37.36% SMA200-15.79% Volume139,078 Change-3.22%
Oct-30-18Initiated Maxim Group Buy $5
Oct-11-18Initiated Dawson James Buy
Feb-28-19 03:02PM  Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner Benzinga
09:15AM  Adial Pharmaceuticals Featured on CBS in San Francisco GlobeNewswire
Feb-26-19 08:00AM  Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters Over-Allotment Option GlobeNewswire -7.05%
Feb-21-19 01:35PM  Four Biotech Stocks Setting The Standard On Thursday (2/21/19) ACCESSWIRE +17.80%
08:45AM  Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering GlobeNewswire
Feb-20-19 09:00AM  Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adials AD04 for its Phase 3 Trial GlobeNewswire -6.13%
Feb-15-19 08:30AM  Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse GlobeNewswire
Feb-12-19 09:33AM  Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder GlobeNewswire -9.71%
Feb-07-19 09:15AM  Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award GlobeNewswire
Feb-01-19 09:20AM  Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder GlobeNewswire +25.78%
Jan-24-19 08:30AM  Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants GlobeNewswire +10.19%
Jan-23-19 01:57PM  What Kind Of Investor Owns Most Of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)? Simply Wall St. -6.90%
Jan-17-19 09:00AM  Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder GlobeNewswire -6.58%
Jan-15-19 09:05AM  Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series GlobeNewswire +14.58%
Jan-10-19 08:00AM  Adial Pharmaceuticals to Present at The 2019 Wall Street Conference GlobeNewswire +12.07%
Dec-27-18 10:25AM  These 4 Healthcare Stocks Are Gaining Speed ACCESSWIRE -8.40%
Dec-26-18 04:18PM  Why Adial Pharmaceuticals (ADIL) Stock Is Soaring Today InvestorPlace +27.47%
11:57AM  4 Healthcare Stocks Getting A Boost On Wednesday, Dec. 26, 2018 ACCESSWIRE
07:30AM  Biotech News Driving These Companies ACCESSWIRE
Dec-24-18 08:00AM  Adial Pharmaceuticals Retires All Outstanding Debt GlobeNewswire +15.12%
07:30AM  Biotech Breakout Candidates ACCESSWIRE
Dec-20-18 06:50AM  Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals ACCESSWIRE -15.66%
Dec-19-18 09:00AM  Adial Pharmaceuticals Announces Amendment to License Agreement with the University of Virginia Licensing & Ventures Group GlobeNewswire +23.39%
Dec-14-18 06:55AM  Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics ACCESSWIRE -8.65%
Dec-13-18 12:49PM  Adial Pharmaceuticals News: ADIL Stock Is Skyrocketing Today InvestorPlace +104.93%
08:00AM  Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl GlobeNewswire
Dec-10-18 08:00AM  Adial Pharmaceuticals Announces Professor Hannu Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki, Finland as Coordinating Principal Investigator for Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire -10.50%
Dec-04-18 06:45AM  Adial Pharmaceuticals, Analysts Coverage, Review and Target ACCESSWIRE
Nov-29-18 10:10AM  Healthcare Stocks Following New Market Trends: Premier Health Group (PHGRF) (PHGI), Alliqua BioMedical, Tonix Pharma, & Adial Pharma ACCESSWIRE +112.12%
09:10AM  Adial Pharmaceuticals Establishes Scientific Advisory Board and Appoints Global Thought Leader in the Field of Alcohol Use Disorder GlobeNewswire
Nov-21-18 08:00AM  Adial Pharmaceuticals Chairman Featured in Doctors Channel Video Discussing Alcohol Use Disorder GlobeNewswire +12.59%
07:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Nov-19-18 08:00AM  Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire
Nov-14-18 08:00AM  Adial Pharmaceuticals Provides Business Update for the Third Quarter of 2018 GlobeNewswire
Nov-08-18 09:20AM  Addiction Drug Developer Adial Pharmaceuticals Receives Notice of Allowance of Canadian Patent for AD04 in Alcohol Use Disorder GlobeNewswire
Oct-23-18 08:00AM  Adial Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference GlobeNewswire +7.88%
Sep-26-18 02:15PM  Adial Pharmaceuticals to Present at The MicroCap Conference on October 1st in New York City ACCESSWIRE
Sep-18-18 07:30AM  Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent GlobeNewswire +9.59%
Sep-12-18 09:00AM  Alcohol Use Disorder Drug Candidate from Adial Pharmaceuticals Shows Positive Stability Results GlobeNewswire
Sep-04-18 08:00AM  Adial Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell this Morning at 9:30 AM Eastern GlobeNewswire
Aug-27-18 09:00AM  Leading Addiction Focused Company Adial Pharmaceuticals Comments on Lancet Article Reporting Alcohol is the Number One Cause of Death Globally Among Ages 15 to 49 GlobeNewswire -7.08%
Aug-15-18 08:00AM  Adial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development GlobeNewswire
Aug-02-18 05:31PM  Dawson James Securities Announces the Closing of Initial Public Offering of Adial Pharmaceuticals, Inc. GlobeNewswire -5.96%
Jul-31-18 04:05PM  Adial Pharmaceuticals Announces Closing of Initial Public Offering GlobeNewswire
Jul-27-18 07:00AM  Adial Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.